{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:28:08Z","timestamp":1793662088108,"version":"4.5.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,18]],"date-time":"2019-04-18T00:00:00Z","timestamp":1555545600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.ophtha.2019.04.017","type":"journal-article","created":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T01:59:20Z","timestamp":1555034360000},"page":"72-84","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":883,"title":["HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration"],"prefix":"10.1016","volume":"127","author":[{"given":"Pravin U.","family":"Dugel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn J.","family":"Jaffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Schmidt-Erfurth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre V.","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Warburton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Weichselberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank G.","family":"Holz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2019.04.017_bib1","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1136\/bjophthalmol-2014-305702","article-title":"Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)","volume":"98","author":"Schmidt-Erfurth","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2019.04.017_bib2","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.ophtha.2019.04.017_bib3","first-page":"343","article-title":"Age-related macular degeneration: advances in management and diagnosis","volume":"4","author":"Yonekawa","year":"2015","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.ophtha.2019.04.017_bib4","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2019.04.017_bib5","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2019.04.017_bib6","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2019.04.017_bib7","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1517\/14656566.2013.787410","article-title":"An update on the pharmacotherapy of neovascular age-related macular degeneration","volume":"14","author":"Freund","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ophtha.2019.04.017_bib8","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jfo.2014.11.015","article-title":"Ranibizumab for exudative age-related macular degeneration: a five year study of adherence to follow-up in a real-life setting","volume":"38","author":"Boulanger-Scemama","year":"2015","journal-title":"J\u00a0Fr Ophtalmol"},{"key":"10.1016\/j.ophtha.2019.04.017_bib9","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3928\/23258160-20140709-04","article-title":"Clinical monitoring of patients with age-related macular degeneration treated with intravitreal bevacizumab or ranibizumab","volume":"45","author":"Kiss","year":"2014","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.ophtha.2019.04.017_bib10","first-page":"1213","article-title":"Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients","author":"Ehlken","year":"2017","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ophtha.2019.04.017_bib11","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1097\/IAE.0000000000001142","article-title":"Metaanalysis of real-world outcomes of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration","volume":"36","author":"Kim","year":"2016","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2019.04.017_bib12","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1172\/JCI71029","article-title":"Recent developments in the treatment of age-related macular degeneration","volume":"124","author":"Holz","year":"2014","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ophtha.2019.04.017_bib13","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","article-title":"Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration","volume":"99","author":"Holz","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2019.04.017_bib14","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.ophtha.2017.03.057","article-title":"Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial","volume":"124","author":"Dugel","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2019.04.017_bib15","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.ophtha.2015.12.030","article-title":"Single-chain antibody fragment VEGF inhibitor RTH258 for neovascular age-related macular degeneration: a randomized controlled study","volume":"123","author":"Holz","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2019.04.017_bib16","unstructured":"TBC. Brolucizumab: a unique single-chain antibody fragment inhibitor of vascular endothelial growth factor."},{"key":"10.1016\/j.ophtha.2019.04.017_bib17","unstructured":"Escher D, Schmidt A, Steiner P, et\u00a0al. Single-chain antibody fragments in ophthalmology. Presented at: 15th EURETINA Congress; September 17\u201320, 2015; Nice, France."},{"key":"10.1016\/j.ophtha.2019.04.017_bib18","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/protein\/gzq028","article-title":"Stability engineering of scFvs for the development of bispecific and multivalent antibodies","volume":"23","author":"Miller","year":"2010","journal-title":"Protein Eng Des Sel"},{"key":"10.1016\/j.ophtha.2019.04.017_bib19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4161\/mabs.2.1.10786","article-title":"Antibody fragments: hope and hype","volume":"2","author":"Nelson","year":"2010","journal-title":"MAbs"},{"key":"10.1016\/j.ophtha.2019.04.017_bib20","doi-asserted-by":"crossref","first-page":"5879","DOI":"10.1073\/pnas.85.16.5879","article-title":"Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain fv analogue produced in escherichia coli","volume":"85","author":"Huston","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ophtha.2019.04.017_bib21","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1126\/science.3140379","article-title":"Single-chain antigen-binding proteins","volume":"242","author":"Bird","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.ophtha.2019.04.017_bib22","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/IAE.0b013e318263cedf","article-title":"Anatomical measures as predictors of visual outcomes in ranibizumab-treated eyes with neovascular age-related macular degeneration","volume":"33","author":"Brown","year":"2013","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2019.04.017_bib23","first-page":"2374","article-title":"Visual acuity response profiles in patients with neovascular age-related macular degeneration treated quarterly with ranibizumab in the EXCITE trial","volume":"50","author":"Eldem","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2019.04.017_bib24","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ajo.2007.10.004","article-title":"Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1","volume":"145","author":"Regillo","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2019.04.017_bib25","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ophtha.2010.09.004","article-title":"Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study","volume":"118","author":"Schmidt-Erfurth","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2019.04.017_bib26","first-page":"3816","article-title":"Effectiveness of quarterly (Q3M) versus monthly (QM) ranibizumab according to initial gains in visual acuity - an analysis of 12 month data from the EXCITE study","volume":"54","author":"Chong","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2019.04.017_bib27","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ajo.2014.04.004","article-title":"Sporadic visual acuity loss in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT)","volume":"158","author":"Kim","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2019.04.017_bib28","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1001\/jamaophthalmol.2014.1019","article-title":"Sustained visual acuity loss in the comparison of age-related macular degeneration treatments trials","volume":"132","author":"Ying","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2019.04.017_bib29","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.ophtha.2013.12.029","article-title":"Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration","volume":"121","author":"Simader","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2019.04.017_bib30","series-title":"EYLEA (aflibercept) Injection [package insert]","year":"2014"},{"key":"10.1016\/j.ophtha.2019.04.017_bib31","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00417-012-2090-9","article-title":"Prospective study evaluating the predictability of need for retreatment with intravitreal ranibizumab for age-related macular degeneration","volume":"251","author":"Mantel","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2019.04.017_bib32","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1016\/j.ophtha.2016.05.016","article-title":"Differential response to anti-VEGF regimens in age-related macular degeneration patients with early persistent retinal fluid","volume":"123","author":"Jaffe","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2019.04.017_bib33","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.neuron.2012.06.018","article-title":"Mechanisms of age-related macular degeneration","volume":"75","author":"Ambati","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.ophtha.2019.04.017_bib35","first-page":"34","article-title":"The pathogenesis of choroidal neovascularization in patients with age-related macular degeneration","volume":"5","author":"Campochiaro","year":"1999","journal-title":"Mol Vis"},{"key":"10.1016\/j.ophtha.2019.04.017_bib36","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12886-016-0207-3","article-title":"The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration--a phase IV randomised clinical trial with ranibizumab: the FLUID study","volume":"16","author":"Arnold","year":"2016","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.ophtha.2019.04.017_bib38","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.ophtha.2012.10.014","article-title":"Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration","volume":"120","author":"Busbee","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2019.04.017_bib39","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Martin","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2019.04.017_bib40","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1016\/j.ophtha.2015.08.009","article-title":"Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results","volume":"122","author":"Wykoff","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2019.04.017_bib41","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2017.07.014","article-title":"Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the TREND study","volume":"125","author":"Silva","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2019.04.017_bib42","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.ophtha.2016.02.046","article-title":"Comprehensive review of ocular and systemic safety events with intravitreal aflibercept injection in randomized controlled trials","volume":"123","author":"Kitchens","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2019.04.017_bib43","series-title":"EYLEA (aflibercept) Injection [prescribing information]","year":"2017"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642018330185?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642018330185?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T14:08:19Z","timestamp":1758982099000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642018330185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0161642018330185"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2019.04.017","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.735560218.793563446","asserted-by":"object"}]},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2019.04.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American Academy of OphthalmologyThis is an open access article under the CC BY-NC-ND license (<inter-ref xlink: href=http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/>http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/<\/inter-ref>).","name":"copyright","label":"Copyright"}]}}